Chief Executive Officer
Mani Mohindru, Ph.D. is a biotechnology executive and President & Chief Executive Officer of Cardiff Oncology, Inc. (Nasdaq: CRDF), where she has served as Interim CEO since January 2026 and as President and CEO since late March 2026, in addition to being a director since 2021.[[3]](https://cardiffoncology.com/management/)[[8]](https://cardiffoncology.com/board-of-directors/) Cardiff Oncology is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, and Mohindru’s appointment to the top role followed her tenure as interim CEO after the departure of the prior chief executive.[[2]](https://www.biospace.com/press-releases/cardiff-oncology-announces-key-leadership-appointments-to-strengthen-executive-team-for-next-phase-of-growth)[[3]](https://cardiffoncology.com/management/)[[6]](https://scr.zacks.com/news/news-details/2026/CRDF-New-CEO-Presents-Phase-II-Readout-article/default.aspx) She has also been a corporate insider through her equity holdings and recent trades in Cardiff Oncology stock.[[2]](https://www.biospace.com/press-releases/cardiff-oncology-announces-key-leadership-appointments-to-strengthen-executive-team-for-next-phase-of-growth)[[6]](https://scr.zacks.com/news/news-details/2026/CRDF-New-CEO-Presents-Phase-II-Readout-article/default.aspx)
Mohindru’s career spans senior leadership roles across multiple biopharmaceutical companies, including serving as Chief Executive Officer of Novasenta Inc. and previously as CEO of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS).[[1]](https://investors.cardiffoncology.com/board-member/mani-mohindru)[[3]](https://cardiffoncology.com/management/)[[4]](https://pmwcintl.com/speaker/mani-mohindru-251_novasenta_2024sv/)[[5]](https://www.bio.org/events/bio-international-convention/speakers/2010597)[[6]](https://scr.zacks.com/news/news-details/2026/CRDF-New-CEO-Presents-Phase-II-Readout-article/default.aspx) Before moving into industry leadership, she spent several years on Wall Street as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse, and ThinkEquity.[[1]](https://investors.cardiffoncology.com/board-member/mani-mohindru)[[3]](https://cardiffoncology.com/management/)[[4]](https://pmwcintl.com/speaker/mani-mohindru-251_novasenta_2024sv/)[[5]](https://www.bio.org/events/bio-international-convention/speakers/2010597)[[6]](https://scr.zacks.com/news/news-details/2026/CRDF-New-CEO-Presents-Phase-II-Readout-article/default.aspx) In addition to her executive roles, she is co‑founder and Board Chair of Roshon Therapeutics, serves on the boards of CytomX Therapeutics, Inc. (Nasdaq: CTMX) and Cardiff Oncology, and has previously served on the board of SAB Biotherapeutics.[[1]](https://investors.cardiffoncology.com/board-member/mani-mohindru)[[3]](https://cardiffoncology.com/management/)[[4]](https://pmwcintl.com/speaker/mani-mohindru-251_novasenta_2024sv/)[[5]](https://www.bio.org/events/bio-international-convention/speakers/2010597) Mohindru holds a Ph.D. in Neurosciences from Northwestern University and a master’s in biotechnology and B.S. in Human Biology (Hons) from the All India Institute of Medical Sciences in India.[[1]](https://investors.cardiffoncology.com/board-member/mani-mohindru)[[3]](https://cardiffoncology.com/management/)[[5]](https://www.bio.org/events/bio-international-convention/speakers/2010597)[[6]](https://scr.zacks.com/news/news-details/2026/CRDF-New-CEO-Presents-Phase-II-Readout-article/default.aspx)
查看完整内部人档案 →